Evidence map›Paper›PMID 8643497›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1996

4-Oxoretinol, a new natural ligand and transactivator of the retinoic acid receptors.

C C Achkar, F Derguini, B Blumberg, A Langston, A A Levin, J Speck, R M Evans, J Bolado, K Nakanishi, J Buck and 1 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Retinoid metabolism: new insights.Journal of molecular endocrinology · 2022
    Review
  3. Review
  4. Anterior patterning genes induced by Zic1 are sensitive to retinoic acid and its metabolite, 4-oxo-RA.Developmental dynamics : an official publication of the American Association of Anatomists · 2022
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Retinoids regulate stem cell differentiation.Journal of cellular physiology · 2011
    Review
  13. Retinoid pathway and cancer therapeutics.Advanced drug delivery reviews · 2010
    Review
  14. From carrot to clinic: an overview of the retinoic acid signaling pathway.Cellular and molecular life sciences : CMLS · 2010
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

C C AchkarDepartment of Pharmacology, Cornell University Medical College, New York, NY 10021, USA.
F Derguini
B Blumberg
A Langston
A A Levin
J Speck
R M Evans
J Bolado
K Nakanishi
J Buck
L J Gudas
Cornell University · US

Funding

Retinoic Acid Binding Proteins: Functional StudiesR01CA043796 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 1987 to 2013
$5.0M
SPATIAL REGULATION OF DEVELOPMENTAL GENE EXPRESSIONR01HD027183 · NICHD · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 1990 to 2009
$3.6M
NCI NIH HHS R01CA43796NICHD NIH HHS R01HD27183NIGMS NIH HHS R01GM45799
6 · The paper itself

Abstract

All-trans-retinoic acid (at-RA) induces cell differentiation in a wide variety of cell types, including F9 embryonic teratocarcinoma cells, and can influence axial pattern formation during embryonic development. We now identify a novel retinoid synthetic pathway in differentiating F9 cells that results in the intracellular production of 4-oxoretinol (4-oxo-ROL) from retinol (vitamin A). Approximately 10-15% of the total retinol in the culture is metabolized to 4-hydroxyretinol and 4-oxo-ROL by the at-RA-treated, differentiating F9 cells over an 18-hr period, but no detectable metabolism of all-trans-retinol to at-RA or 9-cis-retinoic acid is observed in these cells. Remarkably, we show that 4-oxo-ROL can bind and activate transcription of the retinoic acid receptors whereas all-trans-retinol shows neither activity. Low doses of 4-oxo-ROL (e.g., 10(-9) or 10(-10 M) can activate the retinoic acid receptors even though, unlike at-RA, 4-oxo-ROL does not contain an acid moiety at the carbon 15 position. 4-oxo-ROL does not bind or transcriptionally activate the retinoid X receptors. Treatment of F9 cells with 4-oxo-ROL induces differentiation without conversion to the acid and 4-oxo-ROL is active in causing axial truncation when administered to Xenopus embryos at the blastula stage. Thus, 4-oxo-ROL is a natural, biologically active retinoid that is present in differentiated F9 cells. Our data suggest that 4-oxo-ROL may be a novel signaling molecule and regulator of cell differentiation.

Indexed as

AnimalsCell DifferentiationCell LineGene ExpressionHumansMiceReceptors, Retinoic AcidRetinoidsSignal TransductionStereoisomerismTrans-ActivatorsTransfectionTumor Cells, CulturedVitamin AXenopus laevis4-oxoretinolReceptors, Retinoic AcidRetinoidsTrans-ActivatorsVitamin A

Identifiers

PMID8643497
PMCPMC39373
OpenAlexW2094063119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.